首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

2069635

全球癌症胜肽類藥物市場：市場機會、已通過核准藥物劑量、定價、銷售和臨床試驗洞察（2031年）

Global Cancer Peptide Drug Market Opportunity, Approved Drug Dosage, Price, Sales & Clinical Trials Insight 2031

出版日期: 2026年06月01日 | 出版商:

KuicK Research | 英文 800 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

《全球癌症胜肽類藥物市場 - 市場機會、已通過核准藥物劑量、定價、銷售和臨床試驗洞察（2031年）》報告的主要發現和亮點：

調查方法
全球抗癌胜肽類藥物市場機會：到2031年超過250億美元
對全球和區域市場趨勢的洞察
臨床試驗中抗癌胜肽的最新進展：超過240種藥物
依公司、國家、適應症和臨床試驗階段分析癌症胜肽臨床試驗。
已通過核准的抗癌胜肽數量：超過30種
對已通過核准的抗癌胜肽進行分析（依品牌名稱、適應症、公司、地點和合作關係）
已通過核准肽類抗癌藥物的銷售趨勢、專利、劑量和定價分析
毒性胜肽作為癌症胜肽療法的新契機

肽類療法在癌症治療中的必要性及本報告的意義。

全球癌症肽療法市場正轉型為癌症藥物研發領域中一個科學多元化且活躍的臨床研究方向，因為它作為一種分子標靶且用途廣泛的癌症治療方法，具有巨大的潛力。肽類藥物佔據著非常重要的地位，因為它們可合理設計，靶向並調控複雜的癌症生物學過程，包括受體訊號通路、細胞內蛋白質-蛋白質相互作用、標靶化癌症免疫系統以及將藥物遞送至腫瘤微環境。因此，肽類藥物是下一代癌症研究和開發的重要組成部分。

本報告對全球癌症肽療法市場進行了全面分析，重點關注臨床開發、合作與聯合研究活動、投資趨勢以及新科學方法的發展。所有這些目的是幫助投資者、製藥公司和相關人員有效利用基於胜肽的創新療法，在癌症治療領域做出明智的決策。

本報告包含了有關臨床開發的見解

本報告全面分析了處於不同臨床開發階段（從早期人體試驗到後期試驗和監管申報試驗）的胜肽類腫瘤治療計畫，並對現有肽類療法進行了進一步評估。臨床試驗涵蓋了從常見癌症到罕見癌症的多種癌症類型，充分展現了基於胜肽類的解決方案在腫瘤治療中日益成長的重要性。

此外，本分析涵蓋了這些臨床試驗的關鍵特徵，包括單藥治療或聯合治療、目標患者族群、治療線數、給藥途徑、臨床試驗設計、申辦機構、研發合作夥伴以及授權協議。本報告也評估了使用胜肽類藥物治療癌症的臨床試驗的療效和安全性結果，特別關注緩解率、無惡化存活期和總存活期。此外，報告也評估了胜肽類藥物與化療、免疫療法和其他抗腫瘤療法聯合治療的潛力。

引領胜肽類藥物研發的領導企業

在這方面，不僅大型製藥企業，小規模的生物技術公司也對基於胜肽的癌症治療領域做出了重大貢獻。特別是Eli Lilly和Novartis等公司，它們透過許可、合作和放射性配體開發計畫，深度參與了基於胜肽的治療方法。這些公司目前其全面的癌症治療產品線框架內，利用基於胜肽的技術，為多種癌症聯合治療療法和標靶治療療法。

此外，像Avacta Therapeutics和Gate2Brain這樣的小型生物技術公司積極進行基於胜肽的抗癌化合物的臨床前和臨床試驗。這些公司正與一些較成熟的公司合作，將新型胜肽開發成該領域的候選治療藥物。大型製藥企業進入這一領域，加上新興生物技術公司的創新努力，確保了基於胜肽的癌症治療領域持續取得進展。

一份概述癌症肽療法未來發展方向的報告。

本報告系統概述了胜肽類癌症療法的最新進展，說明了從早期研究計畫到臨床試驗和後期檢驗研究的進展。肽類藥物在標靶治療多種癌症方面正發揮越來越效用，涵蓋了從常見固體癌到相對罕見腫瘤的各種類型。其中一個特別值得關注的領域是利用合成胜肽來靶向細胞內蛋白質-蛋白質相互作用以及促進腫瘤生長和存活的致癌性訊號通路。

此外，除了在腫瘤滲透和遞送肽類藥物方面取得的進展外，本文還提及了在不損害身體其他部位的前提下，提高肽類藥物在腫瘤微環境中的選擇性的研究進展。基於胜肽類的免疫療法，包括靶向T細胞增殖和刺激的療法，以及利用肽類藥物引導放射性藥物靶向腫瘤的療法，也得到了討論。總而言之，這些都代表了腫瘤肽類藥物治療領域進行的廣泛研究進展。

Firmagon (Degarelix)
Eligard (Leuprolide)
Lupron (Leuprolide Acetate)
Gonax (Degarelix Acetate)
Trelstar (Triptorelin)
Decapeptyl/Decapeptyl DR (Treptorelin Acetate or Pamoate)
Velcade (Bortizomib)
Ninlaro (Ixazomib)
Kyprolis (Carfilzomib)
Istodax (Romidepsin)
Zoladex (Goserelin)
Cosmegen (Dactinomycin)
Somatuline Depot (Lanreotide)
Sandostatin/ Sandostatin LAR (Octreotide Acetate)
Bynfezia Pen (Octreotide)
Lutathera (Lutetium Lu 177 dotatate)
Mepact (Mifamurtide)
Netspot (Gallium Ga 68 dotatate)
Camcevi (Leuprolide)

第7章市售抗癌胜肽製劑的銷售趨勢

Kyprolis
Zoladex
Lutathera
Sandostatin
Somatuline
Decapeptyl SR
Ninlaro
Velcade
Lupron

第8章依公司、國家、適應症和階段分類的全球肽類抗癌藥物臨床試驗概況

研究
臨床前
階段 0
階段 I
階段 I/II
階段 II
階段 II/III
階段 III
預註冊
已註冊

第9章市售肽類抗癌藥物的臨床研究結果（依公司、國家和適應症）

第10章毒性胜肽：癌症胜肽療法的新時代

蜂毒衍生胜肽
蠍毒衍生胜肽
蛇毒衍生胜肽
蜘蛛毒液衍生胜肽
錐螺毒液衍生胜肽

第11章全球胜肽類抗癌藥物市場動態

有利的市場環境與機會
商業化過程中的挑戰與策略解決方案

第12章治療性胜肽的標靶

訊號傳導通路
細胞週期調節因子
細胞凋亡/細胞死亡調節因子
靶向腫瘤抑制因子的胜肽
轉錄因子靶向胜肽
DNA修復路徑抑制劑
抗血管新生胜肽
免疫調節胜肽
膜破壞/溶瘤胜肽

第13章胜肽類藥物與傳統癌症療法的比較

肽療法與化療
肽療法和免疫療法
肽療法與基因療法的比較

第14章競爭格局

3B Pharmaceuticals
APIM Therapeutics
AsclepiX Therapeutics
Bicycle Therapeutics
Biohaven Labs
BrightPath Biotherapeutics
Bristol-Myers Squibb
Gnubiotics Sciences
IDP Pharma
Janux Therapeutics
Medikine
Modulation Therapeutics
Novartis
Oncopeptides
Parabilis Medicines
PeptiDream
Perspective Therapeutics
Pharm-Sintez
Sapience Therapeutics
Vigeo Therapeutics

簡介目錄圖表

Global Cancer Peptide Drug Market Opportunity, Approved Drug Dosage, Price, Sales & Clinical Trials Insight 2031 Report Finding & Highlights:

Research Methodology
Global Cancer Peptide Drug Market Opportunity: > USD 25 Billion By 2031
Global & Regional Market trends Insight
Insight On Cancer Peptides In Clinical Trials: > 240 Drugs
Cancer Peptide Clinical Trials Insight By Company, Country, Indication & Phase
Number Of Approved Cancer Peptides: > 30 Drugs
Insight On Approved Cancer Peptide By Brand Name, Indication, Company, Location, Collaborations
Approved Peptide Cancer Drugs Sales Insights, Patent, Dosage and Price Analysis
Venom Peptides As New Opportunity For Cancer Peptide Therapy

Need For Peptide Therapeutics In Cancer Treatment & Why This Report?

Global cancer peptide therapeutics market has transformed itself into a scientifically diverse yet active clinical field in cancer drug development due to its highly desirable potential for molecularly targeted and versatile cancer treatment modalities. Peptides hold a key position as they can be rationally designed to target and modulate complex cancer biology: receptor signaling pathways, intracellular protein interactions, cancer immune system targeting, and delivery to the tumor environment. As such, they represent a significant aspect of the next generation oncology research and development market.

In this report, we undertake a comprehensive analysis of global cancer peptide therapeutics market, highlighting clinical development efforts, partnership and collaboration activities, investment trends, and the development of novel scientific avenues, all aimed at assisting investors, pharmaceutical companies and stakeholders make their decision in the cancer treatment landscape with an effective use of peptide based innovative approaches.

Clinical Development Insight Included In Report

The report offers an extensive analysis of current oncology programs involving peptides at various levels of clinical development, starting with the first human studies to advanced stages and even registration studies, as well as the further assessment of already existing peptide therapies. The scope of clinical trials covers various cancer types, both commonly encountered and quite rare ones, thus demonstrating the increasing importance of peptide based solutions in oncology treatment.

The analysis also covers the important characteristics of these clinical trials, including whether monotherapy or combinations were used, targeted patient populations, lines of therapy, routes of administration, clinical trial designs, sponsoring organizations, development partners, and licensing agreements. The report also provides an assessment of the results achieved in terms of efficacy and safety from clinical trials using peptides in oncology therapies, specifically focusing on the percentage of responders, progression free survival rates, and overall survival figures. It further evaluates the potential for peptides to be used in combination therapies with chemotherapy, immunotherapies, and other antineoplastic treatments.

Major Companies Driving Peptide Therapeutics R&D

In this regard, the peptide oncology landscape includes strong contributions from big pharma companies as well as small biotechnology firms. In particular, significant involvement of companies like Eli Lilly and Novartis in peptide based approaches through licensing, partnerships, and radioligand development programs can be observed. Peptide based techniques are currently used by these companies in the framework of their comprehensive oncology pipelines as part of combination approaches or targeted treatment strategies for a wide variety of cancers.

Additionally, smaller biotechnology companies like Avacta Therapeutics and Gate2Brain have been actively developing promising peptide based anticancer compounds in preclinical and clinical studies. Such companies have been collaborating with more mature players on translating novel peptides into treatment candidates within the field. The involvement of big pharma in this field, together with the innovative efforts of emerging biotechnology firms, ensures ongoing progress in peptide oncology.

Report Indicating Future Development Of Cancer Peptide Therapeutics

This report outlines an organized assessment of the ongoing development of peptide therapies against cancer, detailing developments from early research programs through to clinical trials and even to later stage validation studies. Peptides continue to demonstrate increasing utility in targeting multiple cancers, ranging from more common solid cancers to some of the rarer forms. One particular area of interest is the use of synthetic peptides in targeting protein-protein interactions within the cell and oncogenic signal transduction pathways involved in driving tumor proliferation and survival.

Moreover, developments in tumor penetration and delivery of peptides in cancer are noted, along with efforts towards improving selectivity within the tumor environment without causing toxicity to other parts of the body. In addition, developments in the peptide based immunotherapy approaches, including those targeting T-cell proliferation and stimulation, have been discussed, alongside peptide guidance of radiopharmaceuticals to tumors. Overall, this shows a wide range of ongoing progress in the field of peptide therapy in oncology

1. Introduction To Peptide Therapeutics

1.1 Overview Of Peptide Therapeutics
1.2 Classification Of Anticancer Peptides
1.3 Designing & Functioning of Peptide Drugs
1.4 Significance Of Peptides As Cancer Therapeutics
1.5 Role of Peptides in Cancer Immunotherapy

2. Different Approaches Of Peptides In Cancer Therapeutics

2.1 Hormonal Peptides
2.2 Peptide Based Radionuclide Drug Carriers
2.3 Peptide Vaccines
2.4 Cytotoxic Drug Carriers
2.5 Anticancer Peptides
2.6 Tumor-Targeting and Cell-Penetrating Peptides
2.7 Peptide Nanomedicines
2.8 Receptor Antagonist and PPI-Modulating Peptides
2.9 Emerging Approaches

3. Global Cancer Peptide Drug Market Insight

3.1 Current Market Scenario
3.2 Future Market Opportunities

4. Cancer Peptide Research & Market Trends by Country

4.1 US
4.2 China
4.3 Europe
4.4 Canada
4.5 UK
4.6 Australia
4.7 Japan
4.8 South Korea
4.9 India
4.10 Middle East
4.11 Latin America

5. Cancer Peptide Research & Market Trends By Indication

5.1 Breast Cancer
5.2 Hematological Malignancies
5.3 Urothelial Cancer
5.4 Prostate Cancer
5.5 Lung Cancer
5.6 Skin Cancer
5.7 Gastrointestinal Cancer
5.8 Gynecological Cancer
5.9 CNS Cancers

6. Marketed Cancer Peptides Drugs & Generics Insight - Availability, Cost, Dosage, Indication & Patent Insight

6.1 Firmagon (Degarelix)
6.1 Eligard (Leuprolide)
6.2 Lupron (Leuprolide Acetate)
6.3 Gonax (Degarelix Acetate)
6.4 Trelstar (Triptorelin)
6.5 Decapeptyl/Decapeptyl DR (Treptorelin Acetate or Pamoate)
6.6 Velcade (Bortizomib)
6.7 Ninlaro (Ixazomib)
6.8 Kyprolis (Carfilzomib)
6.9 Istodax (Romidepsin)
6.10 Zoladex (Goserelin)
6.11 Cosmegen (Dactinomycin)
6.12 Somatuline Depot (Lanreotide)
6.13 Sandostatin/ Sandostatin LAR (Octreotide Acetate)
6.14 Bynfezia Pen (Octreotide)
6.15 Lutathera (Lutetium Lu 177 dotatate)
6.16 Mepact (Mifamurtide)
6.17 Netspot (Gallium Ga 68 dotatate)
6.18 Camcevi (Leuprolide)

7. Marketed Cancer Peptides Drugs Sales Insight

7.1 Kyprolis
7.2 Zoladex
7.3 Lutathera
7.4 Sandostatin
7.5 Somatuline
7.6 Decapeptyl SR
7.7 Ninlaro
7.8 Velcade
7.9 Lupron

8. Global Peptide Cancer Drugs Clinical Trials Insight By Company, Country, Indication & Phase

8.1 Research
8.2 Preclinical
8.3 Phase 0
8.4 Phase I
8.5 Phase I/II
8.6 Phase II
8.7 Phase II/III
8.8 Phase III
8.9 Preregistration
8.10 Registered

9. Marketed Peptide Cancer Drugs Clinical Insight By Company, Country & Indication

10. Venom Peptides: New Era For Cancer Peptide Therapy

10.1 Bee Venom-Derived Peptides
10.2 Scorpion Venom-Derived Peptides
10.3 Snake Venom-Derived Peptides
10.4 Spider Venom-Derived Peptides
10.5 Cone Snail Venom-Derived Peptides

11. Global Peptide Cancer Drug Market Dynamics

11.1 Favorable Market Parameters & Opportunities
11.2 Commercialization Challenges & Strategic Solutions

12. Therapeutic Peptide Targets

12.1 Signal Transduction Pathways
12.2 Cell Cycle Regulators
12.3 Apoptosis/Cell-Death Modulators
12.4 Tumor Suppressor Targeting peptides
12.5 Transcription Factor-Targeting Peptides
12.6 DNA Repair Pathway Inhibitors
12.7 Anti-Angiogenic Peptides
12.8 Immunomodulatory Peptides
12.9 Membrane-Disrupting/Oncolytic Peptides

13. Peptide Drugs v/s Conventional Cancer Therapeutics

13.1 Peptide Therapeutics v/s Chemotherapy
13.2 Peptide Therapeutics vs Immunotherapies
13.3 Peptide Therapeutics vs Gene Therapy

14. Competitive Landscape

14.1 3B Pharmaceuticals
14.2 APIM Therapeutics
14.3 AsclepiX Therapeutics
14.4 Bicycle Therapeutics
14.5 Biohaven Labs
14.6 BrightPath Biotherapeutics
14.7 Bristol-Myers Squibb
14.8 Gnubiotics Sciences
14.9 IDP Pharma
14.10 Janux Therapeutics
14.11 Medikine
14.12 Modulation Therapeutics
14.13 Novartis
14.14 Oncopeptides
14.15 Parabilis Medicines
14.16 PeptiDream
14.17 Perspective Therapeutics
14.18 Pharm-Sintez
14.19 Sapience Therapeutics
14.20 Vigeo Therapeutics

簡介目錄圖表

List of Figures

Figure 1-1: Functional Role Of Peptides In The Human Body
Figure 1-2: Historical Timeline Of Peptide Therapeutics
Figure 1-3: Anticancer Peptides - Classification
Figure 1-4: Traditional Structure-Based Design Strategies Used In Peptide Drug Discovery
Figure 1-5: Peptides - Significance As Cancer Therapeutics
Figure 1-6: Peptides - Role In Cancer Immunotherapy
Figure 2-1: Hormonal Peptides In Cancer Therapy
Figure 2-2: GnRH Therapy Mechanism
Figure 2-3: Somatostatin-Based Targeted Therapy
Figure 2-4: GHRH-IGF Axis
Figure 2-5: Peptide Radiopharmaceutical Structure
Figure 2-6: Peptide-Based Radionuclide Drug Carriers
Figure 2-7: Theranostic Workflow
Figure 2-8: Peptide Vaccine Immunotherapy
Figure 2-9: Peptide-Based Drug Delivery In Cancer
Figure 2-10: Structural Classification Of Anticancer Peptides
Figure 2-11: Mechanistic Overview Of Anticancer Peptides
Figure 2-12: Functional Roles Of Tumor-Targeting Peptides & Cell-Penetrating Peptides In Cancer Therapy
Figure 2-13: Major Internalization Pathways Of Cell-Penetrating Peptides
Figure 2-14: Design Of Bifunctional Peptide Constructs
Figure 2-15: Activatable Cell-Penetrating Peptide Strategy
Figure 2-16: Integration Of Peptides & Nanotechnology For Precision Oncology
Figure 2-17: Classification Of Receptor Antagonist & PPI-Modulating Peptides
Figure 2-18: Inhibition Of Oncogenic Protein-Protein Interactions
Figure 2-19: Modern Technologies For Peptide Discovery
Figure 2-20: Stabilization Of a-Helical Peptides By Stapling
Figure 2-21: Structural Advantages Of Cyclic Peptide Therapeutics
Figure 2-22: Foldamer-Based Mimics Of Protein Secondary Structures
Figure 2-23: Artificial Intelligence-Driven Next-Generation Peptide Design
Figure 3-1: Global - Peptide Therapeutic Market Size (US$ Billion), 2024 - 2031
Figure 3-2: Global - Peptide Oncology Drugs Market Size (US$ Billion), 2024 - 2031
Figure 3-3: Global Cancer Peptide Therapeutics Market - Future Opportunities
Figure 5-1: 17-328 Phase 1 (NCT03362060) Study - Initiation & Completion Year
Figure 5-2: TH1902-CTR-0001 Phase 1 (NCT04706962) Study - Initiation & Completion Year
Figure 5-3: PQ203-001 Phase 1 (NCT07190469) Study - Initiation & Completion Year
Figure 5-4: NCI-2014-02621 Phase 1 (NCT02334865) Study - Initiation & Completion Year
Figure 5-5: 20190675 Phase 1 (NCT04365179) Study - Initiation & Completion Year
Figure 5-6: BT5528-100 Phase 1/2 (NCT04180371) Study - Initiation & Completion Year
Figure 5-7: 202412028 Phase 1 (NCT06529822) Study - Initiation & Completion Year
Figure 5-8: PRMC 20-027 Phase 1 (NCT05010200) Study - Initiation & Completion Year
Figure 5-9: TB001 Version 2.1_2024-10-25 Phase 1/2 (NCT06400160) Study - Initiation & Completion Year
Figure 5-10: RAD301.2022-001 Phase 1 (NCT05799274) Study - Initiation & Completion Year
Figure 5-11: CFXX489A12101 Phase 1 (NCT06562192) Study - Initiation & Completion Year
Figure 5-12: CGCJ904A12101 Phase 1 (NCT07261631) Study - Initiation & Completion Year
Figure 5-13: NCI-2017-01781 Phase 1 (NCT03300817) Study - Initiation & Completion Year
Figure 5-14: TH1902-CTR-0001 Phase 1 (NCT04706962) Study - Initiation & Completion Year
Figure 5-15: NeoLIPA Phase 2 (NCT06651151) Study - Initiation & Completion Year
Figure 5-16: KEYNOTE-D18 Phase 3 (NCT05155254) Study - Initiation & Completion Year
Figure 5-17: ST316-101 Phase 1 (NCT05848739) Study - Initiation & Completion Year
Figure 5-18: FOG-001-101 Phase 1/2 (NCT05919264) Study - Initiation & Completion Year
Figure 5-19: RYZ801-101 Phase 1/2 (NCT06726161) Study - Initiation & Completion Year
Figure 5-20: AMPLIFY-7P Phase 1/2 (NCT05726864) Study - Initiation & Completion Year
Figure 5-21: CDMRP-CA170223 Phase 2 (NCT03796884) Study - Initiation & Completion Year
Figure 5-22: TH1902-CTR-0001 Phase 1 (NCT04706962) Study - Initiation & Completion Year
Figure 5-23: CBX-12-201 Phase 2 (NCT06315491) Study - Initiation & Completion Year
Figure 5-24: BT5528-100 Phase 1/2 (NCT04180371) Study - Initiation & Completion Year
Figure 5-25: RAD301.2022-001 Phase 1 (NCT05799274) Study - Initiation & Completion Year
Figure 5-26: NCI-2015-00694 Phase 2 (NCT02455557) Study - Initiation & Completion Year
Figure 5-27: INTERCEPT-H3 Phase 1 (NCT04808245) Study - Initiation & Completion Year
Figure 5-28: ViCTOry Phase 1 (NCT05609994) Study - Initiation & Completion Year
Figure 5-29: NeoVax Phase 1 (NCT02287428) Study - Initiation & Completion Year
Figure 5-30: PRiME Phase 1 (NCT03299309) Study - Initiation & Completion Year
Figure 5-31: ST101-101 Phase 1/2 (NCT04478279) Study - Initiation & Completion Year
Figure 6-1: Firmagon - Patent Issue & Expiration Years
Figure 6-2: Firmagon - Price Per Unit & Supply Of Powder For Subcutaneous Injection (US$), June'2026
Figure 6-3: Firmagon - Starting & Maintenance Dosage (mg)
Figure 6-4: Firmagon - Treatment Costs Of Initial Cycle & Maintenance Cycle (US$), June'2026
Figure 6-5: Eligard - Cost Of Subcutaneous Powder For Injection By Dose (US$), June'2026
Figure 6-6: Eligard - Recommended Dosage For Prostate Cancer On Monthly Basis (mg)
Figure 6-7: Eligard - Prostate Cancer Annual Treatment Cost By Dose (US$), June'2026
Figure 6-8: Lupron Sustained Release Preparation - Patent Issue & Expiration Year
Figure 6-9: Lupron - Price Of Lupron Depot Intramuscular Kits (US$), June'2026
Figure 6-10: Lupron - Price of Lupron Depot Intramuscular Powder By Dose (US$), June'2026
Figure 6-11: Lupron - Annual Treatment Costs By Intramuscular Kit Dose (US$), June'2026
Figure 6-12: Lupron - Annual Treatment Costs By Intramuscular Powder Dose (US$), June'2026
Figure 6-13: Gonax - Cost of Supply Of Powder For Subcutaneous Injection (US$), June'2026
Figure 6-14: Gonax - Starting & Maintenance Dosage (mg)
Figure 6-15: Trelstar - Patent Issue & Expiration Year
Figure 6-16: Trelstar - Cost Per Unit & Supply Of Powder For Intramuscular Injection (US$), June'2026
Figure 6-17: Trelstar - Annual Treatment Cost By Dose (US$), June'2026
Figure 6-18: Decapeptyl SR - Price For A Supply of 3mg, 11.25mg & 22.5mg Powder For Injection (GBP/US$), June'2026
Figure 6-19: Decapeptyl SR - Recommended Dosage For Prostate Cancer (mg/week)
Figure 6-20: Decapeptyl SR - Annual Prostate Cancer Treatment Cost By Dose (US$), June'2026
Figure 6-21: Velcade - Price Of 3.5 mg Powder For Injection (US$), June'2026
Figure 6-22: Bortizomib - Price Of Injectable Powder For Injection By Dose (US$), June'2026
Figure 6-23: Ninlaro - Patent Issue & Expiration Year
Figure 6-24: US & EU - Price Per Unit & Supply Of Ninlaro Capsule (US$), June'2026
Figure 6-25: Ninlaro - Recommended Dose & Dose Reductions For Multiple Myeloma Treatment (mg/week)
Figure 6-26: Kyprolis - Price Of 10mg, 30mg & 60mg Intravenous Powder For Injection (US$), June'2026
Figure 6-27: Kyprolis - Initial Dose & Maintenance Dose For Multiple Myeloma Treatment (mg/m2/week)
Figure 6-28: Kyprolis - Initial Dose & Maintenance Dose As Monotherapy For Multiple Myeloma Treatment (mg/m2 Twice a Week)
Figure 6-29: Romidepsin - FDA Approval Year By Indication
Figure 6-30: Istodax & Romidepsin - Price Per Supply Of Intravenous Powder (US$), June'2026
Figure 6-31: Zoladex - Cost Of Implant By Dose (US$), June'2026
Figure 6-32: Zoladex - Recommended Dose For Prostate Cancer Management On Monthly Basis (mg/week)
Figure 6-33: Zoladex - Annual Treatment Cost Using 3.6mg & 10.8mg Implant (US$), June'2026
Figure 6-34: Dactinomycin - Price For Generic & Branded 0.5 mg Powder For Injection (US$), June'2026
Figure 6-35: Somatuline Depot - Price Per Unit & supply of Subcutaneous Solution By Dose (US$), June'2026
Figure 6-36: Lanreotide - Price Per Unit & Supply Of Subcutaneous Solution (US$), June'2026
Figure 6-37: Somatuline Depot - Treatment Cost Of 1 Cycle & Annual Treatment Cost of GEP-NETs & Carcinoid Syndrome (US$), June'2026
Figure 6-38: Sandostatin - Price Per Unit & 10-Vial Supply By Dose (US$), June'2026
Figure 6-39: Sandostatin LAR - Price Of Intramuscular Powder For Injection By Dose (US$), June'2026
Figure 6-40: Octreotide - Price Per Unit & Supply Of 10 mL Injectable Solution (US$), June'2026
Figure 6-41: Octreotide - Price Per Unit & Supply Of 5 mL Injectable Solution (US$), June'2026
Figure 6-42: Octreotide - Price Per Unit & Supply Of Intramuscular Powder For Injection By Dose (US$), June'2026
Figure 6-43: Sandostatin - Mean Initial Dose For Treatment Of Carcinoid Tumor & Vasoactive Intestinal Peptide Tumor (mg/day)
Figure 6-44: Bynfezia Pen - Patent Issue & Expiration Year
Figure 6-45: Bynfezia Pen - Price Per Unit & Supply Of Subcutaneous Solution (US$), June'2026
Figure 6-46: Bynfezia Pen - Mean Dose For First 2 Week & Subsequent Weeks (mcg/day)
Figure 6-47: Lutathera - Patent Issue & Expiration Years
Figure 6-48: Lutathera - RDP & ODE Regional Expiry Years
Figure 6-49: Mepact - Recommended Number Of Dose Administration/Week for 12 & 24 Weeks Treatment
Figure 7-1: Kyprolis - Global Sales (US$ Million), 2020-2026
Figure 7-2: Kyprolis - Global Sales By Region (US$ Million), Q1'2026
Figure 7-3: Kyprolis - Global Sales By Region (US$ Million), 2025
Figure 7-4: Kyprolis - US Annual Sales (US$ Million), 2020-2026
Figure 7-5: Kyprolis - ROW Annual Sales (US$ Million), 2020-2026
Figure 7-6: Zoladex - Global Sales (US$ Million), 2020-2026
Figure 7-7: Zoladex - Global Sales By Region (US$ Million), Q1'2026
Figure 7-8: Zoladex - Global Sales By Region (US$ Million), 2025
Figure 7-9: Zoladex - US Annual Sales (US$ Million), 2020-2026
Figure 7-10: Zoladex - Europe Annual Sales (US$ Million), 2020-2026
Figure 7-11: Zoladex - Emerging Markets Annual Sales (US$ Million), 2020-2026
Figure 7-12: Zoladex - ROW Annual Sales (US$ Million), 2020-2026
Figure 7-13: Lutathera - Global Sales (US$ Million), 2020-2026
Figure 7-14: Lutathera - Global Sales By Region (US$ Million), 2024-2026
Figure 7-15: Lutathera - Global Quarterly Sales (US$ Million), Q1-Q4'2025
Figure 7-16: Lutathera - US Quarterly Sales (US$ Million), Q1-Q4'2025
Figure 7-17: Lutathera - ROW Quarterly Sales (US$ Million), Q1-Q4'2025
Figure 7-18: Sandostatin - Global Sales (US$ Million), 2020-2026
Figure 7-19: Sandostatin - Global Quarterly Sales (US$ Million), Q1-Q4'2025
Figure 7-20: Sandostatin - US Annual Sales (US$ Million), 2020-2026
Figure 7-21: Sandostatin - US Quarterly Sales (US$ Million), Q1-Q4'2025
Figure 7-22: Sandostatin - ROW Annual Sales (US$ Million), 2020-2026
Figure 7-23: Sandostatin - ROW Quarterly Sales (US$ Million), Q1-Q4'2025
Figure 7-24: Somatuline - Global Sales (US$ Million), 2020-2026
Figure 7-25: Somatuline - Global Quarterly Sales (US$ Million), Q1-Q4'2025
Figure 7-26: Somatuline - North America Sales (US$ Million), 2022-2026
Figure 7-27: Somatuline - NA Quarterly Sales (US$ Million), Q1-Q4'2025
Figure 7-28: Somatuline - Europe Sales (US$ Million), 2022-2026
Figure 7-29: Somatuline - Europe Quarterly Sales (US$ Million), Q1-Q4'2025
Figure 7-30: Somatuline - ROW Sales (US$ Million), 2022-2026
Figure 7-31: Somatuline - ROW Quarterly Sales (US$ Million), Q1-Q4'2025
Figure 7-32: Decapeptyl - Global Sales (US$ Million), 2020-2026
Figure 7-33: Decapeptyl - Global Quarterly Sales (US$ Million), Q1-Q4'2025
Figure 7-34: Decapeptyl - Europe Sales (US$ Million), 2022-2026
Figure 7-35: Decapeptyl - Europe Quarterly Sales (US$ Million), Q1-Q4'2025
Figure 7-36: Decapeptyl - ROW Sales (US$ Million), 2022-2026
Figure 7-37: Decapeptyl - ROW Quarterly Sales (US$ Million), Q1-Q4'2025
Figure 7-38: Ninlaro - Global Sales (US$ Million), 2020-2026
Figure 7-39: Ninlaro - Global Quarterly Sales (US$ Million), Q1-Q4'2025
Figure 7-40: Velcade - Global Sales (US$ Million), 2020-2024
Figure 7-41: Velcade - Global Quarterly Sales (US$ Million), Q1-Q4'2023
Figure 7-42: Global - Lupron Annual Sales (US$ Million), 2019-2021
Figure 7-43: US - Lupron Annual Sales (US$ Million), 2019-2021
Figure 7-44: ROW - Lupron Annual Sales (US$ Million), 2019-2021
Figure 8-1: Global - Peptide Cancer Drug Clinical Pipeline by Phase (Number of Drugs), 2026
Figure 10-1: Venom-Derived Peptides In Cancer Therapy
Figure 10-2: Bee Venom-Derived Peptides In Cancer Therapy
Figure 10-3: Melittin - Mechanism Of Action
Figure 10-4: Scorpion Venom-Derived Peptides In Cancer Therapy
Figure 10-5: Hallmarks Of Cancer Targeted By Scorpion Venom Peptides
Figure 10-6: Snake Venom-Derived Peptides As Anticancer Agents
Figure 10-7: Spider Venom-Derived Peptides In Cancer Therapy
Figure 10-8: Nanotechnology-Enhanced Lycosin-I Therapy
Figure 10-9: Cone Snail Venom-Derived Peptides In Cancer Therapy
Figure 11-1: Global Peptide Cancer Drug Market - Drivers & Opportunities
Figure 11-2: Global Peptide Cancer Drug Market - Key Challenges & Corresponding Solutions
Figure 12-1: Classification & Molecular Targets of Anticancer Therapeutic Peptides
Figure 12-2: Therapeutic Peptide Targets In Cancer Signal Transduction Networks
Figure 12-3: Cell Cycle & Major Peptide Intervention Points
Figure 12-4: Checkpoint & Mitotic Targets For Therapeutic Peptides
Figure 12-5: Major Peptide Targets In Apoptosis Signaling
Figure 12-6: BH3 Mimetic Mechanism
Figure 12-7: Transcription Factor-Targeting Peptides In Cancer
Figure 12-8: Mechanisms Of Peptide Inhibition Of Transcription Factors
Figure 12-9: Dominant-Negative Peptide Strategy
Figure 12-10: Challenges & Solutions In Transcription Factor Peptide Therapy
Figure 12-11: DNA Damage Response & Sites Of Peptide Intervention
Figure 12-12: Synthetic Lethality In DNA Repair
Figure 12-13: Anti-Angiogenic Peptides - Examples
Figure 12-14: Anti-Angiogenic Peptides - Classification
Figure 12-15: Overall Mechanism Of Immunomodulatory Peptides
Figure 12-16: Dual Action Pathway
Figure 12-17: Membrane-Disrupting Peptides - Overall Mechanism
Figure 12-18: Cancer Selectivity Mechanism

List of Tables

Table 1-1: Source Or Chemical Nature Of Early Peptides
Table 2-1: Classification Of Hormonal Peptide Therapeutics
Table 2-2: Major Receptor Targets For Peptide Radionuclide Delivery
Table 2-3: Types Of Peptide Cancer Vaccines
Table 2-4: Common Cytotoxic Payloads
Table 2-5: Types Of Peptide-Based Drug Delivery Systems
Table 2-6: Classification Of Cell-Penetrating Peptides
Table 2-7: Comparison Between TTPs & CPPs
Table 2-8: Stimuli-Responsive Peptide Nanomedicine Systems
Table 2-9: Nanocarrier Platforms In Peptide Nanomedicine
Table 2-10: Comparison Of Conventional Drug Delivery & Peptide Nanomedicine
Table 2-11: Peptide Engineering Strategies For PPI Inhibitors
Table 2-12: Types Of PPI-Modulating Peptides
Table 2-13: Comparison Of PPI-Modulating Peptides & Receptor Antagonist Peptides
Table 2-14: Limitations Addressed By Emerging Peptide Therapeutics
Table 2-15: Comparison Of Emerging Peptide Platforms
Table 2-16: Artificial Intelligence Tools In Peptide Design
Table 2-17: Advantages Of AI-Guided Peptide Discovery
Table 3-1: Global Cancer Peptide Therapeutics Market - Recent Fundings & Investments
Table 3-2: Global Cancer Peptide Therapeutics Market - Recent Collaborations
Table 6-1: Trelstar - Recommended Dose (mg/week)
Table 6-2: Velcade - Dosage Regimen For Patients With Previously Untreated Multiple Myeloma
Table 6-3: Kyprolis -Expiration Year Of Patents
Table 10-1: Broad Classification Of Venom Sources For ACPs
Table 10-2: Most Common Venom Sources Investigated For Anticancer Peptides
Table 10-3: Well-Known Venom-Derived Anticancer Peptides & Their Mechanisms
Table 10-4: Major Bee Venom Peptides & Their Anticancer Functions
Table 10-5: Major Scorpion Venom Peptides & Their Anticancer Activities
Table 10-6: Major Snake Venom-Derived Anticancer Peptides
Table 10-7: Major Spider Venom-Derived Anticancer Peptides
Table 10-8: Major Cone Snail Venom Peptides & Anticancer Activities
Table 12-1: MAPK Signaling Components Targeted By Therapeutic Peptides
Table 12-2: Major Signal Transduction Pathways & Their Cancer Functions
Table 12-3: Delivery & Engineering Strategies For Cell Cycle Peptides
Table 12-4: DNA Repair Targets & Therapeutic Outcomes
Table 12-5: Types Of Immunomodulatory Peptides